Tri-complex of Compound-2, KRAS G12V, and CypA

Tri-complex of Compound-2, KRAS G12V, and CypA Descriptor: (2R)-N-[(1P,8S,10S,14S,21M)-22-ethyl-21-{2-[(1R)-1-methoxyethyl]pyridin-3-yl}-18,18-dimethyl-9,15-dioxo-16-oxa-10,22,28-triazapentacyclo[18.5.2.1~2,6~.1~10,14~.0~23,27~]nonacosa-1(25),2(29),3,5,20,23,26-heptaen-8-yl]-3-methyl-2-(N-methylacetamido)butanamide (non-preferred name), CHLORIDE ION, GTPase KRas, ... Authors: Tomlinson, A.C.A, Chen, A, Knox, J.E, Yano, J.K. Deposit date: 2024-04-18 Release date: 2025-03-19 Last modified: 2025-04-09 Method: X-RAY DIFFRACTION (1.14 Å) Cite: Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J.Med.Chem., 68, 2025